Non-lysosomal glucosylceramidase (GBA2)

Non-lysosomal glucosylceramidase (GBA2) is a membrane-associated enzyme that catalyzes the hydrolysis of glucosylceramide into glucose and ceramide at a neutral pH, primarily within the endoplasmic reticulum and Golgi apparatus (UniProt Q9HCG7; PMID: 15907795). Unlike its lysosomal counterpart GBA1, GBA2 belongs to the glycosyl hydrolase family 116 and is not localized to the lysosome (PMID: 20637546). This enzyme plays a critical role in maintaining sphingolipid homeostasis across various tissues, including the brain and testes. Mutations in the GBA2 gene are associated with severe neurodegenerative disorders, such as hereditary spastic paraplegia type 46 and autosomal recessive cerebellar ataxia (PMID: 22305528; PMID: 25701536). In lysosomal storage diseases like Gaucher disease and Niemann-Pick type C, GBA2 activity is often significantly upregulated, which can exacerbate cellular toxicity through the accumulation of downstream metabolites like glucosylsphingosine (PMID: 24503053). Pharmacological inhibition of GBA2 is a known effect of certain iminosugars like miglustat, which is primarily used in substrate reduction therapy for Gaucher disease (PMID: 12446905). While GBA2 inhibition may offer therapeutic benefits in some contexts, it has also been linked to reversible male infertility in animal models, presenting a significant therapeutic challenge (PMID: 12446905). Understanding the balance of GBA2 activity is therefore essential for developing targeted treatments for sphingolipid-related pathologies.

Other names

Glucosylceramidase 2Beta-glucosidase 2Bile acid beta-glucosidaseGBA2Glucocerebrosidase 2

Inhibition of non-lysosomal glucosylceramide hydrolysis to modulate sphingolipid levels and reduce toxic metabolite accumulation.